• Sherwin-Williams-RC.JPG-w1200.jpg
    • Sushi-Ukai-w1200.jpg
      July VIBEs at Lunch - Sushi Ukai
    • BioScan-Tek-Ribbon-Cutting.JPG-w1200.jpg
      BioScan Tek
    • Pulte-Ribbon-Cutting.JPG-w1200.jpg
      Loretto Club by Pulte Homes
    • Strohschein-Ribbon-Cutting.JPG-w1200.jpg
      Strohschein Law Group
  • Mindful TMS Neurocare First to Offer Unique Neuronavigation-based TMS Treatment for Depression

    • Share:
    January 15, 2019
    Mindful TMS Neurocare First to Offer Unique Neuronavigation-based TMS Treatment
    for Depression
    Wheaton, Ill.—(January 14th, 2019)  There is new hope for Chicago-area residents battling chronic and treatment-resistant depression. Mindful TMS Neurocare is opening a new clinic in the Chicago area on January 18th, offering patients neuronavigation-based transcranial magnetic stimulation (TMS) which is a new and enhanced option to improve the existing TMS treatment for depression.
    Depression is a mental health disorder that affects over 16 million adults in the US and approximately 15 percent of the Illinois population, according to the Illinois Department of Public Health. The disorder is characterized by symptoms such as sadness, hopelessness, loss of interest or pleasure in daily activities, trouble sleeping or sleeping too much, and reduced appetite. Recently, we have seen a significant rise in depression, especially among teenagers and young adults. Risks factors for depression include genetic traits, substance abuse, or traumatic life experiences. Although depression is a serious mental health illness, it is treatable.
    Treatment for patients suffering from depression can include anti-depressants, cognitive behavior therapy, or psychotherapy. However, a significant percentage of patients do not benefit from these approaches. For treatment-resistant patients, TMS was developed and approved by the Food and Drug Administration in 2008. The revolutionary treatment has helped thousands of patients for whom antidepressants and therapy have provided limited to no symptom relief. TMS is non-invasive and non-systemic, which renders the treatment virtually free of side effects. This eliminates side effects that are commonly experienced by medication.
     “I am so honored to be invited to the Inauguration of Mindful TMS Neurocare Center. Their neuronavigation system is very impressive, providing an unmatched precision in positioning the TMS coil over a specified target based on an individual’s MRI scan. This is known to improve response and remission rates significantly,” said Murali S. Rao, MD, FAACLP, professor and chair of the Department of Psychiatry & Behavioral Neurosciences at the Stritch School of Medicine, Loyola University Chicago.
    There is increasing evidence for the clinical use of neuronavigation-based TMS in many disorders including OCD, anxiety, stroke rehabilitation, Parkinson’s disease, migraines, tinnitus, perinatal depression, postpartum depression, and disorders of addiction.
    This state-of-the-art TMS technology, previously relegated to academic institutions, is now being made available to the general public, by Mindful TMS Neurocare Center, to help improve the quality of mental health care.”
    To introduce this new technology to the Chicago area, Mindful TMS will be holding an Inaugural Open House on Friday January 18th from 9 a.m. to 5 p.m. and on Saturday, January 19th from 9 a.m. to 3 p.m. at 1737 South Naperville Rd, Suite 203, in Wheaton, Ill. Mindful TMS Neurocare staff will be providing live demonstrations of neuronavigation-based TMS.
    To register or inquire about the open house, please email tmckelvy@mindfultms.com. For more information about Mindful TMS Neurocare, visit www.mindfultms.com.
    Contact:  Chris Martin; cmartin@davidjamesgroup.com; 630.670.2745

  • What's Happening What's Happening